Han T, Barcos M, Emrich L, Ozer H, Gajera R, Gomez G A, Reese P A, Minowada J, Bloom M L, Sadamori N
J Clin Oncol. 1984 Jun;2(6):562-70. doi: 10.1200/JCO.1984.2.6.562.
Bone marrow biopsies were prospectively performed on 75 patients with chronic lymphocytic leukemia (CLL). There was a highly significant relationship (p less than 0.002) between clinical stages and bone marrow infiltration patterns. Ten (50%) of 20 patients with diffuse patterns died; the estimated median survival time for these patients was 87 months. In contrast, only six (11%) of 55 patients with nondiffuse patterns died; the estimated median survival time for these patients could not be computed. When both clinical stage and infiltration pattern were evaluated for survival, a highly significant association between clinical stage and survival time was still observed (p less than 0.003) whereas bone marrow infiltration pattern was no longer significant. A significant association was also observed between bone marrow infiltration patterns and absolute lymphocyte counts (p less than 0.0005), Fc-receptor-positive cells (p less than 0.002), 3H-thymidine uptake of leukocytes (p less than 0.01), serum alkaline phosphatase levels (p less than 0.05), monoclonal urinary-free light chain status (p less than 0.05), and cytogenetics of leukemic cells (p less than 0.05). These observations lead to the conclusion that in an overall prognostic evaluation of patients with CLL, although bone marrow histopathology may have no additional value over a well-established clinical staging system, as a whole, it may be of clinically predictive value in disease progression of patients with stage I and II.
对75例慢性淋巴细胞白血病(CLL)患者进行了前瞻性骨髓活检。临床分期与骨髓浸润模式之间存在高度显著的相关性(p<0.002)。20例弥漫性模式患者中有10例(50%)死亡;这些患者的估计中位生存时间为87个月。相比之下,55例非弥漫性模式患者中只有6例(11%)死亡;这些患者的估计中位生存时间无法计算。当同时评估临床分期和浸润模式对生存的影响时,仍观察到临床分期与生存时间之间存在高度显著的关联(p<0.003),而骨髓浸润模式不再具有显著性。骨髓浸润模式与绝对淋巴细胞计数(p<0.0005)、Fc受体阳性细胞(p<0.002)、白细胞的3H-胸腺嘧啶核苷摄取(p<0.01)、血清碱性磷酸酶水平(p<0.05)、单克隆游离轻链状态(p<0.05)以及白血病细胞的细胞遗传学(p<0.05)之间也存在显著关联。这些观察结果得出结论,在CLL患者的总体预后评估中,尽管骨髓组织病理学相对于完善的临床分期系统可能没有额外价值,但总体而言,它可能对I期和II期患者的疾病进展具有临床预测价值。